Robert W. Baird restated their buy rating on shares of Agilent Technologies, Inc. (NYSE:A) in a research note released on Friday morning. The brokerage currently has a $72.00 target price on the medical research company’s stock.

Several other equities research analysts also recently commented on A. BidaskClub downgraded Agilent Technologies from a strong-buy rating to a buy rating in a report on Monday, July 31st. Jefferies Group LLC reissued a buy rating and issued a $66.00 price objective on shares of Agilent Technologies in a report on Wednesday, August 9th. J P Morgan Chase & Co reissued an overweight rating and issued a $70.00 price objective on shares of Agilent Technologies in a report on Wednesday, August 16th. Bank of America Corporation reissued an equal weight rating on shares of Agilent Technologies in a report on Tuesday, August 15th. Finally, Janney Montgomery Scott increased their price objective on Agilent Technologies from $65.00 to $70.00 and gave the company a buy rating in a report on Wednesday, August 16th. Five research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The stock currently has a consensus rating of Buy and an average target price of $68.34.

Shares of Agilent Technologies (A) opened at $69.36 on Friday. The company has a market capitalization of $22,106.37, a P/E ratio of 28.98, a PEG ratio of 2.07 and a beta of 1.27. The company has a quick ratio of 2.76, a current ratio of 3.30 and a debt-to-equity ratio of 0.37. Agilent Technologies has a twelve month low of $42.92 and a twelve month high of $70.81.

Agilent Technologies (NYSE:A) last released its quarterly earnings data on Monday, November 20th. The medical research company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.62 by $0.05. The company had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.17 billion. Agilent Technologies had a return on equity of 16.96% and a net margin of 15.30%. The firm’s revenue for the quarter was up 7.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.59 EPS. analysts forecast that Agilent Technologies will post 2.58 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, January 24th. Investors of record on Tuesday, January 2nd will be paid a $0.149 dividend. This represents a $0.60 dividend on an annualized basis and a yield of 0.86%. The ex-dividend date is Friday, December 29th. This is a boost from Agilent Technologies’s previous quarterly dividend of $0.13. Agilent Technologies’s dividend payout ratio is 25.24%.

In other Agilent Technologies news, Director Boon Hwee Koh sold 4,500 shares of the stock in a transaction on Wednesday, August 30th. The stock was sold at an average price of $63.63, for a total transaction of $286,335.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Patrick Kaltenbach sold 5,000 shares of the stock in a transaction on Friday, September 8th. The stock was sold at an average price of $65.26, for a total value of $326,300.00. Following the transaction, the insider now owns 45,143 shares in the company, valued at approximately $2,946,032.18. The disclosure for this sale can be found here. In the last 90 days, insiders sold 107,709 shares of company stock worth $7,195,576.

A number of hedge funds have recently bought and sold shares of A. Dupont Capital Management Corp bought a new position in Agilent Technologies during the 3rd quarter worth $101,000. Balentine LLC increased its position in shares of Agilent Technologies by 2.9% in the second quarter. Balentine LLC now owns 1,794 shares of the medical research company’s stock worth $106,000 after purchasing an additional 50 shares during the period. Sun Life Financial INC increased its position in shares of Agilent Technologies by 26,144.4% in the second quarter. Sun Life Financial INC now owns 2,362 shares of the medical research company’s stock worth $140,000 after purchasing an additional 2,353 shares during the period. Acrospire Investment Management LLC increased its position in shares of Agilent Technologies by 92.3% in the second quarter. Acrospire Investment Management LLC now owns 2,500 shares of the medical research company’s stock worth $148,000 after purchasing an additional 1,200 shares during the period. Finally, Parallel Advisors LLC increased its position in shares of Agilent Technologies by 5.3% in the second quarter. Parallel Advisors LLC now owns 2,623 shares of the medical research company’s stock worth $157,000 after purchasing an additional 131 shares during the period.

TRADEMARK VIOLATION NOTICE: This piece was first published by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.watchlistnews.com/agilent-technologies-inc-a-receives-buy-rating-from-robert-w-baird/1725644.html.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.

Analyst Recommendations for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.